Loma Linda University Children's Hospital

Summary

Loma Linda University Children's Hospital is a medical facility located in Loma Linda, California. This center is recognized for care of Brain Anoxia Ischemia, Hypoxic-Ischemic Encephalopathy, Cardiac Arrest, Heart Attack, Acute Respiratory Distress Syndrome and other specialties. Loma Linda University Children's Hospital is involved with conducting 21 clinical trials across 55 conditions. There are 4 research doctors associated with this hospital, such as Cheryl P Sanchez-Kazi, MD, Ruofan Yao, MD, MPH, Ciprian P Georghe, MD, and Gregory Aaen, MD.

Top PIs

Clinical Trials running at Loma Linda University Children's Hospital

Focal Segmental Glomerulosclerosis

T-Cell Lymphoblastic Leukemia

Acute T-Cell Leukemia

Acute Lymphoblastic Leukemia

Acute Respiratory Distress Syndrome

Extracorporeal Membrane Oxygenation

Respiratory Distress Syndrome

Abdominal Wall Defects

Gastroschisis

Neuromyelitis Optica

LIPOSORBER® LA-15 System

for Focal Segmental Glomerulosclerosis

This trial tests a blood-filtering device called the LIPOSORBER® LA-15 System in adults with kidney issues from FSGS who haven't had success with other treatments or have had severe side effects. The device helps by cleaning the blood to protect the kidneys.

Recruiting

1 award

N/A

2 criteria

Liposorber LA-15 Therapy

for Focal Segmental Glomerulosclerosis

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia). Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.

Recruiting

1 award

N/A

5 criteria